This article is more than 5 years old. Information may no longer be current.

Pfizer second quarter revenue up

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Pfizer’s revenues for the second quarter of 2005 grew 1% over the same period last year, to $12.43 billion, the company said in a press release. Net income was reported to be $3.46 billion.

Among the fastest-growing medicines in Pfizer’s portfolio is the glaucoma drug Xalatan/Xalacom (latanoprost); sales grew 17% over the previous year’s quarter to $341 million, the company reported.

Macugen (pegaptanib sodium injection), which Pfizer markets jointly with Eyetech Pharmaceuticals, “attained the No. 1 rank in Verispan monthly physician claims share for neovascular AMD” within 3 months of its launch, the company noted.

“A recent tracking survey shows that more than 74% of all retina specialists in the U.S. have administered Macugen to their patients,” Pfizer said in its press release. The drug has also been approved for marketing in Canada and Brazil and is awaiting regulatory approval in the European Union, Australia and Switzerland.

The company’s cardiovascular portfolio remains its strongest suit, posting second quarter revenues of $4.47 billion. This is followed by Pfizer’s drugs for central nervous system disorders, which had quarterly revenues of $1.54 billion, the release said.